Arrowhead Pharmaceuticals, Inc. ARWR R2K
Company Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Why Investors Should Care
Revenue has grown at a 84.2% CAGR over the past five years.
Recent Developments
- Sep 2025 Revenue of $829.45M (+23258.2% YoY); net profit $-1.63M.
- Trailing 12 Months Year-on-year growth — revenue -86.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 84.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 84.15% |
| 1 Year: | -86.40% |
Stock Price Performance
| 1 Year: | +285.92% |
| 6 Months: | +8.93% |
| 3 Months: | +7.69% |
| 1 Month: | -3.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)36.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 84.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARWR Arrowhead Pharmaceuticals, Inc. R2K | 71.82 | -32.65 | $10.12B | 0.00% | 8.27% | -42.37% | 84.15% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 3.51M | 650.12K | 727.38K | 11.26M | 34.66M | 48.15M | 42.70M | 43.29M | 29.45M | 23.53M | 27.38M | 7.63M | 21.30M | 32.81M | 45.89M | 27.44M | 151.81M | 32.41M | 62.55M | 146.27M | 15.82M | 3.55M | 0 | 0 | - | 542.71M | 27.77M | 256.47M | 264.03M | 73.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 161.51M | 193.32M | 212.37M | 223.22M | 215.00M |
| Operating Income | -15.99M | -25.23M | -19.34M | -21.26M | -19.34M | -21.80M | -14.90M | -6.13M | -5.71M | -10.25M | -13.81M | -15.03M | -15.92M | -11.17M | 10.95M | 22.01M | 18.60M | 9.64M | -4.85M | -22.24M | -15.95M | -50.12M | -24.05M | -28.23M | -31.87M | -63.32M | 41.55M | -72.91M | -42.13M | 48.16M | -102.70M | -136.54M | -126.19M | -176.14M | - | 381.20M | -165.55M | 44.11M | 40.81M | -141.26M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 397.34M | -148.48M | 64.20M | 57.17M | -107.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.64M | 24.38M | 21.69M | 22.50M | 23.85M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 369.62M | -179.09M | 36.12M | 28.27M | -137.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75M | -437.00K | 20.00M | 29.00K | 7.00K |
| Net Income | -15.94M | -24.75M | -19.26M | -20.82M | -19.42M | -22.22M | -12.09M | -6.04M | -5.52M | -10.73M | -13.20M | -14.88M | -15.61M | - | 12.04M | 23.90M | 20.34M | - | -2.67M | -19.84M | -13.61M | - | -20.73M | -26.82M | -29.92M | -62.87M | 44.37M | -72.05M | -41.33M | 48.67M | -102.95M | -132.86M | -125.30M | -170.79M | - | 370.44M | -175.24M | -23.75M | 30.81M | -132.73M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.18 | -0.18 | -0.18 | -0.12 | 0.13 | 0.24 | 0.21 | 0.12 | -0.03 | -0.20 | -0.13 | -0.48 | -0.20 | -0.26 | -0.29 | -0.60 | 0.41 | -0.68 | -0.39 | 0.45 | -0.96 | -1.24 | -1.02 | -1.38 | -1.39 | 2.75 | -1.26 | - | 0.22 | -0.93 |
| R&D Expense | 7.49M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.00M | 133.10M | - | - | 177.20M | 173.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2005 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 296.14K | 146.88K | 290.27K | 175.00K | 382.00K | 158.33K | 31.41M | 16.14M | 168.80M | 87.99M | - | 243.23M | 240.74M | 3.55M | 829.45M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 421.74M | 445.74M | 604.63M | 731.10M |
| Operating Income | - | -5.83M | -9.83M | -21.09M | -24.59M | -53.28M | -95.97M | -81.74M | -37.00M | -55.94M | 61.19M | -93.16M | - | -178.51M | -205.00M | -601.08M | 98.35M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -162.29M | -175.67M | -561.51M | 164.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 18.33M | 32.35M | 89.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -172.71M | -206.49M | -612.46M | 51.53M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.79M | 2.78M | -2.77M | 21.42M |
| Net Income | -6.73M | -5.77M | -3.13M | -21.13M | -31.14M | -58.63M | -91.94M | -81.72M | -34.38M | -54.45M | 67.97M | -84.55M | - | -176.06M | -205.28M | -599.49M | -1.63M |
| Diluted EPS | - | -0.90 | -0.40 | - | - | - | - | - | -0.47 | -0.65 | 0.69 | -0.84 | - | -1.67 | -1.92 | -5.00 | -0.01 |
| R&D Expense | - | 529.60K | 3.28M | 5.39M | 8.71M | 23.14M | 47.27M | - | - | - | - | - | - | - | 353.19M | 505.87M | 607.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2003 | Sep 2004 | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | 12.35M | 15.89M | 16.53M | 37.33M | 182.82M | 132.27M | 128.18M | 104.02M | 111.61M | 349.85M | 522.50M | - | 691.94M | 765.55M | 1.14B | 1.39B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 405.30M | 416.47M | 695.47M | 950.64M |
| Cash & Equivalents | - | - | - | - | - | - | 2.02M | 6.85M | 7.51M | 3.38M | 19.11M | 132.51M | 81.21M | 85.37M | 24.84M | 30.13M | 221.80M | 143.58M | - | 108.00M | 110.89M | 76.21M | 88.71M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.41M | 0 | 0 | 6.82M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 273.60M | 478.39M | 948.74M | 881.88M |
| Current Liabilities | - | - | - | - | - | - | - | 4.28M | 2.58M | 5.33M | 8.73M | 11.85M | 15.90M | 25.64M | 18.70M | 12.36M | 97.07M | 40.68M | - | 138.85M | 105.46M | 103.17M | 195.49M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 393.18M | 214.88M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.58M | 115.17M | 510.55M | 366.28M |
| Total Equity | 1.42M | 11.23M | 28.03M | 31.61M | 26.46M | 12.30M | 4.86M | 9.05M | 12.79M | 10.01M | 27.50M | 166.54M | 110.18M | 95.58M | 81.42M | 95.80M | 244.59M | 461.78M | - | 398.52M | 271.34M | 185.44M | 466.05M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105.96M | 107.31M | 124.38M | 138.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -64.43M | -23.94M | -47.22M | 173.03M | -95.80M | - | -136.13M | -153.89M | -462.85M | 179.55M |
| Investing Cash Flow | - | - | - | - | - | 13.45M | -48.64M | -7.43M | -47.75M | -240.78M | - | -5.42M | -96.16M | -420.07M | -129.29M |
| Financing Cash Flow | - | - | - | - | - | 55.13M | 12.06M | 59.95M | 66.38M | 257.95M | - | 65.19M | 253.05M | 870.52M | 74.01M |
| Capital Expenditure | -9.67K | -479.71K | -296.88K | -1.72M | -1.97M | -3.86M | -7.92M | -1.42M | -12.00M | -11.95M | - | -52.78M | -176.74M | -141.47M | -22.67M |
| Free Cash Flow | - | - | - | - | - | -68.29M | -31.86M | -48.64M | 161.03M | -107.75M | - | -188.91M | -330.63M | -604.32M | 156.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -76.36M | 3.01M | -12.40M | 124.26M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2005 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -3,319.5% | -14,358.6% | -8,471.3% | -30,443.6% | -25,124.1% | -51,627.1% | -117.8% | -346.5% | 36.3% | -105.9% | - | -73.4% | -85.2% | -16,927.1% | 11.9% |
| Net Margin % | - | - | -1,056.6% | -14,383.6% | -10,729.2% | -33,503.0% | -24,068.3% | -51,614.6% | -109.5% | -337.3% | 40.3% | -96.1% | - | -72.4% | -85.3% | -16,882.4% | -0.2% |
| ROE % | -24.0% | -63.8% | -24.5% | -211.0% | -113.3% | -35.2% | -83.4% | -85.5% | -42.2% | -56.8% | 27.8% | -18.3% | - | -44.2% | -75.7% | -323.3% | -0.3% |
| ROCE % | - | -72.2% | -73.9% | -188.3% | -86.0% | -31.2% | -82.5% | -79.7% | -43.4% | -56.4% | 24.2% | -19.3% | - | -32.3% | -31.1% | -58.0% | 8.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.89% | 18.16M | $1.31B |
| 2 | Avoro Capital Advisors LLC | 7.60% | 10.70M | $769.44M |
| 3 | FMR, LLC | 5.16% | 7.27M | $522.54M |
| 4 | Vanguard Portfolio Management LLC | 5.07% | 7.15M | $513.88M |
| 5 | State Street Corporation | 4.61% | 6.50M | $467.14M |
| 6 | Vanguard Capital Management LLC | 4.28% | 6.03M | $433.79M |
| 7 | Geode Capital Management, LLC | 3.04% | 4.28M | $307.69M |
| 8 | Fred Alger Management, LLC | 2.37% | 3.34M | $240.36M |
| 9 | Invesco Ltd. | 2.33% | 3.28M | $235.91M |
| 10 | Vestal Point Capital, LP | 1.62% | 2.27M | $163.60M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARWR
Arrowhead gains EU authorisation for Redemplo in evolving FCS market
EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Apple, Bloom Energy, Circle Internet Group, First Solar, Halliburton, IBM, Intuit, Newmont, SK hynix, and More
Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and Mizuho made some bold calls you may not see coming.…
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.…
The Long Climb Back For Ionis Stock
A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuat…
ARWR — Frequently Asked Questions
What is the current share price of Arrowhead Pharmaceuticals, Inc. (ARWR)?
As of 2026-07-15 16:51 PDT, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at $71.82 on NasdaqGS. Its 52-week range is $14.71 to $86.97.
What is the market capitalisation of ARWR?
Arrowhead Pharmaceuticals, Inc. (ARWR) has a market capitalisation of $10.12B on NasdaqGS.
What is the P/E ratio of ARWR?
ARWR trades at a trailing price-to-earnings (P/E) ratio of -32.65. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 16.46.
What is the return on equity (ROE) of ARWR?
ARWR has a return on equity (ROE) of -42.37%. Its return on capital employed (ROCE) is 8.27%.
Is ARWR a good stock to buy?
This page provides a data-driven analysis of Arrowhead Pharmaceuticals, Inc. (ARWR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.